Trial Search Results

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institutes of Health (NIH)

Intervention(s):

  • Procedure: Tumor biopsy
  • Procedure: Phlebotomy

Eligibility


Inclusion Criteria:

   - Histologically confirmed squamous cell carcinoma of the head and neck sites or
   non-small cell lung cancer, or relatives of patients with histologically confirmed
   squamous cell carcinoma of the head and neck.

   - Able to sign a Stanford IRB approved consent form

Exclusion criteria:

   - Refuse or unable to sign an IRB approved consent form.

   - Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rachel Freiberg
650-725-0438
Recruiting